Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.
Evaluation of Using a Nanotechnology Structured Water Magnalife® to Achieve Controlled Blood Glucose Level in Type 2 Diabetic Patients.
1 other identifier
interventional
387
0 countries
N/A
Brief Summary
Type 2 DM is due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical, and physical properties of water molecules and improve the bioavailability of this nano-water. Objective: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with type 2 diabetes mellitus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2016
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 3, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2018
CompletedFirst Submitted
Initial submission to the registry
September 5, 2019
CompletedFirst Posted
Study publicly available on registry
September 9, 2019
CompletedSeptember 10, 2019
September 1, 2019
1.6 years
September 5, 2019
September 6, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HbA1c
measurement of HbA1c
three months
Study Arms (2)
Magnalife
ACTIVE COMPARATORthe group of patients receiving the nanotechnology structured water
Ordinary water
PLACEBO COMPARATORthe group of patients receiving ordinary water
Interventions
Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
Ordinary bottled water
Eligibility Criteria
You may qualify if:
- Type 2 diabetic patients
You may not qualify if:
- Malignancy
- Steroids
- Immunotherapy
- Chemotherapy
- Radiotherapy
- Chronic infections
- Drugs that antagonize or synergies insulin effects
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Sami AKM, Amin KH, Kurmanji MT. The Novel Use of Nanotechnology Structured Water Magnalife to Control Blood Glucose Level in Type 2 Diabetic Patients. Diabetes. 2018;67(Supplement 1):1155.
RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ali K M.Sami, Ph.D.
College of Medicine, University of Sulaimani
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- doctor, lecturer
Study Record Dates
First Submitted
September 5, 2019
First Posted
September 9, 2019
Study Start
July 3, 2016
Primary Completion
February 16, 2018
Study Completion
February 16, 2018
Last Updated
September 10, 2019
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- Six months from the time it is public until one year after the date of being public.
- Access Criteria
- To obtain the IPD, an email should be sent to the investigator to ask for IPD and then get access to the plan.
The plan may include the levels of HbA1c, the medications used by the patients, the duration of their DM. But no personal data of the patients can be shared according to the agreement with patients under study.